RXRA and chronic myelogenous leukemia, BCR-ABL1 positive: We also assessed the effect of RXRA ligand treatment combined with imatinib on improving TKI sensitivity in CML cell lines, primary cells in-vitro, and in a CML cell line-derived xenograft mice model.